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ABSTRACT
Purpose. Despite advances in therapy for the treatment of
metastatic colorectal cancer, many patients die of hepatic
disease. Current immunotherapeutic strategies are likely
limited by inhibitory signals from the tumor. To success-
fully eliminate tumor deposits within an organ, an
appropriate immunologic milieu to amplify antitumor
responses must be developed.
Methods. We used a murine model utilizing the CT26
colon cancer cell line to analyze primary and memory
tumor-specific T-cell responses induced by an attenuated
actin A and internalin B deleted immunodominant tumor-
associated antigen expressing strain of Listeria monocyt-
ogenes for the treatment of metastatic colorectal cancer.
Results. Treatment of mice bearing established hepatic
metastases with this L. monocytogenes strain led to the
generation of a strong initial tumor-specific cytotoxic
CD8? T-cell response that successfully treated 90% of
animals. Tumor antigen-specific central and effector
memory T cells were also generated and protected against
tumor rechallenge. These cell populations, when measured
before and after tumor rechallenge, showed a marked
expansion of antigen-specific effector CD8? effector
memory T cells. This strain of L. monocytogenes was able
to down-modulate the expression of the immune check-
point molecule, PD-1, within the tumor microenvironment
but had variable effects on CTLA-4 expression.
Conclusions. This L. monocytogenes strain generated a
highly effective antitumor T-cell response, providing a
basis for the development of this vaccine platform in
patients with liver metastases.
Cancer immunotherapy is successful when it eliminates
tumor cells and prevents recurrence with the generation of
an antigen-specific memory T-cell response. Previous
strategies that focused on peptides or cytokine-secreting
cancer vaccines, adoptive cytotoxic T-cell transfer, anti-
body therapy, and dendritic cell therapy have had variable
success in generating primary antitumor responses.1–11
However, all failed to generate robust acquired immunity
and memory T cells targeted toward tumors, likely as a
result of the inability to provide appropriate inflamma-
tory stimuli, so-called danger signals, within the tumor
microenvironment. Additionally, effective therapy must
overcome multiple mechanisms used by tumors to inhibit
antigen-specific immunity including regulatory T cells
(Treg) and inhibitory co-receptor signaling.
Previously, we utilized a genetically attenuated strain of
Listeria monocytogenes (with deletion of both actin A and
internalin B genes, referred to as LMD), a gram-positive
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bacterium, in a model of hepatic colorectal cancer metas-
tases. We found that LMD generated strong innate
antitumor immune responses through activation of NK and
NKT cells. A smaller contribution to antitumor effects
resulted from cytotoxic CD8? T cells with an interferon-c
dominant helper T cell (Th1) phenotype.12–14 We developed
a new strain of LMD that expressed AH1 (LMD-AH1), the
tumor-associated immunodominant antigen of the murine
colon cancer cell line CT26 to increase recruitment of the
adaptive immune response.15,16 Recently, L. monocytoge-
nes was shown to elicit antigen-specific CD8? T-cell
responses when used as a vaccine vector in breast and
ovarian cancer models. 17–19 By means of this strategy, we
elicited strong cytotoxic tumor-specific CD8? T-cell
responses directly within the liver tumor microenvironment,
and achieved lasting cure. We also demonstrated that
treatment diminished the expression of PD-1, a key immune
checkpoint coinhibitory receptor in CD8? T-cell–dendritic
cell interactions. This receptor, when expressed on T cells,
renders tumor-infiltrating lymphocytes anergic.20–22 We
also observed the generation of a tumor antigen–specific
pool of both central and effector memory T cells in treated
mice that survived tumor challenge, with a subsequent
expansion of effector memory CD8? T cells in those mice
able to reject tumor rechallenge.
METHODS
Animals, Tumor Cell Line, and Peptides
BALB/c mice (6–8 weeks old, female) were purchased
from the National Cancer Institute and were treated in
compliance with the Johns Hopkins Animal Care and Use
Committee. CT26 cancer cells were grown in RPMI 1640
medium with 10% heat-inactivated fetal calf serum
(HyClone), 1 mM sodium pyruvate, 2 mM L-glutamine,
nonessential amino acids (1% of 1009 stock), penicillin
(100 U/ml), streptomycin (100 U/ml), and 3 ll b-mercap-
toethanol.15 AH1 (SPSYVYHQF), a H-2Ld-restricted
peptide, and b-gal (TPHPARIGL) control peptide were
synthesized by the Johns Hopkins University Protein/Pep-
tide/DNA facility with 99% purity.23
Listeria Monocytogenes
LMD was provided by Aduro BioTech.14,24 The AH1
peptide expressing strain (LMD-AH1) was constructed
from the LMD strain with the AH1 sequence inserted into
the gene encoding the actin A—ovalbumin fusion protein
with oligonucleotide-directed polymerase chain reaction.
The construct was cloned into the pPL2 integration vector
and integrated at the tRNA Arg locus of the bacterial
chromosome.25 Molecular constructs were confirmed by
sequencing.
Murine Hepatic Metastasis Model and Treatment
Mice were provided isolated hepatic metastases via a
hemispleen injection technique (Supplementary Fig. 1).26
Treatment doses of LMD or LMD-AH1 were administered
intraperitoneally (i.p.) every 3 days at a dose equivalent to
one-tenth the experimentally determined lethal dose (0.19
LD50). A dose of 50 mg/kg of cyclophosphamide (Sigma)
was provided i.p.27
Analysis and Isolation of Spleen- and Liver-infiltrating
Lymphocytes
Lymphocytes from livers and spleens were isolated and
processed as previously described.14 After isolation, cells
were blocked with Fc III/II R Antibody (BD PharMingen)
and stained with commercially available CD3, CD4, CD8,
CD62L, CD95, PD-1 (eBioscience). Intracellular staining
of CTLA-4 or Foxp3 was done with an intracellular cyto-
kine kit (eBioscience) and analyzed on a FACSCalibur
flow cytometer. After lymphocyte isolation, 1:1000 of
Golgistop (BD Biosciences) and 20 lg/ml of AH1 or b-gal
peptide were added (2:1000) and coincubated at 37C for
5 h, followed by intracellular staining with interferon-c
(BD PharMingen). Tetramer staining was performed on
liver-infiltrating lymphocytes after magnetic bead CD8?
T-cell isolation (Milteny Biotec) and stained with an AH1-
or b-gal-specific Ld tetramer, provided by Jill Slansky.
In Vivo CTL Assay
In vivo cytotoxic activity of antigen-specific T cells was
assayed as previously described.28 The CFSEhigh-labeled
cells were pulsed with 10 lg/ml (1:1000) of AH1 peptide,
and CFSElow-labeled cells were pulsed with 10 lg/ml
b-gal control peptide. Forty hours after injection of the
CFSE-labeled target cells, the ratio of CFSElow to CFSEhigh
cells was determined by flow cytometry.
Subcutaneous Flank and Pulmonary Metastases CT26
Tumor Challenge
For primary challenge and rechallenge experiments,
mice were injected with 1 9 105 CT26 cells subcutane-
ously. Tumor volume was calculated as 0.5 (A 9 B2), with
B equal to the smaller diameter. Pulmonary metastases
were provided via tail vein injection with 5 9 104 for
primary challenge or 1 9 105 CT26 cells for rechallenge
experiments.
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AH1 Antigen-Specific CD8 Memory T-Cell Analysis
Hepatic metastases survivors from each treatment group
and tumor-naive mice underwent partial splenectomy.
Splenic lymphocytes underwent AH1-specific tetramer and
extracellular staining for CD8, CD62L, and CD95 (eBio-
science). After 3 days, mice received a flank injection of
CT26 tumor cells, and 8 days later underwent completion
splenectomy with repeat staining.
Statistical Analysis
Statistical analyses were performed with GraphPad
Prism 5.0. Log-rank analysis was performed for survival
experiments. The Mann-Whitney was used for analysis of
the AH1 antigen-specific memory CD8? T-cell experi-
ment. Two-way analysis of variance (ANOVA) with
Bonferroni posttest analysis was performed for all other
analyses. A P value of \0.05 was considered statistically
significant. All experiments were repeated three times, and
representative results of each experiment are shown.
RESULTS
Tumor-Associated Antigen Expressing Listeria
Monocytogenes (LMD-AH1) has Enhanced Antitumor
Efficacy Against CT26 Metastases
The therapeutic effect of LMD-AH1 was compared to
treatment with LMD or no treatment (NT) after hepatic
metastases tumor challenge. Mice treated with LMD-AH1
exhibited 90% survival (P = 0.016 vs. LMD and
P \ 0.001 vs. NT) compared with 40% survival for mice
treated with LMD (P = 0.002 vs. NT) (Fig. 1b), consistent
with our previously published reported efficacy for
LMD.14,26
In our initial work, when mice were challenged with
CT26 pulmonary metastases and treated with the LMD
strain, no mice survived, likely as a result of a lack of a
systemically generated effector CD8? T-cell response.
However, after tail vein injection, 40% of mice treated with
LMD-AH1 survived (P = 0.011) (Fig. 1c). This finding
was corroborated by Brockstedt et al., who used an AH1-
A5 peptide expressing strain of LMD to achieve a survival
a
b c d
FIG. 1 Treatment with tumor antigen-expressing Listeria (LMD-
AH1) improves survival. a Treatment protocol for b–d. b Balb/c mice
were treated with injections of 0.1 9 LD50 of LMD-AH1 or LMD on
days 3, 6, and 9 after CT26 tumor challenge on day 0 with
hemisplenectomy liver metastases model; n = 10 per group. Log-
rank test, *P \ 0.001 LMD-AH1 versus NT; P = 0.016 LMD-AH1
versus LMD; **P = 0.002 LMD versus NT. c Balb/c mice were
treated with LMD-AH1 or LMD on days 3, 6, and 9 after CT26 tumor
challenge via tail vein injection; n = 10 per group. Log-rank test,
*P = 0.011. d Mice were treated with cyclophosphamide (Cy) on day
7 followed with LMD-AH1 on days 8, 11, and 14 or LMD-AH1
alone; n = 10 per group. Log-rank test, P = 0.006 LMD-
AH1 ? Cy versus LMD-AH1; *P \ 0.001 LMD-AH1 ? Cy versus
NT; **P = 0.013 LMD-AH1 versus NT
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benefit after intravenous CT26 challenge.24 Of note, in both
the liver and pulmonary metastases model, at the time of
completion of the survival experiment, mice that were alive
showed no evidence of disease, while those that died ear-
lier all had evidence metastatic disease.
Because Tregs represent a critical inhibitor of tumor
immunity, the expression of Foxp3 on CD4? T cells was
studied within the tumor microenvironment in the liver and
on splenocytes. Increased numbers of Foxp3? Tregs were
present in all tumor-challenged groups (Supplementary
Fig. 3). Given these findings, we attempted to improve
survival of LMD-AH1 treated mice by combining treat-
ment with a Treg inhibitory dose of cyclophosphamide. We
previously demonstrated efficacy when combining cyclo-
phosphamide and LMD in a low tumor burden model due
to the depletion of Treg cells and a subsequent improve-
ment in the numbers and activation of antigen-specific
CD8? T cells.14 Given the improved efficacy of the LMD-
AH1 strain, we waited until a higher tumor burden (mac-
roscopic disease) was present before beginning treatment.
Mice provided a single dose of 50 mg/kg of cyclophos-
phamide (Cy) on day 7 followed by LMD-AH1 on days 8,
11, and 14 had 60% survival, compared with 10% for
LMD-AH1 alone (P = 0.006 LMD-AH1 ? Cy vs. LMD-
AH1; P \ 0.001 LMD-AH1 ? Cy vs. NT; P = 0.013
LMD-AH1 vs. NT) (Fig. 1d).
Mice Treated with LMD-AH1 Have a Sustained
Increase in Antigen-Specific CD8? T Cells
To assess tumor antigen–specific CD8? T cells, we
stained isolated liver lymphocytes with an AH1 peptide
loaded Ld tetramer. Those treated with LMD-AH1 had the
highest percentage of CD8? AH1-specific T cells (1.89%)
compared with LMD (0.11%), NT (0.46%), or naive
(0.13%) (Fig. 2a). The peak on day 9 was followed by a
lower but steady population through day 11 for LMD-AH1
treated mice (Fig. 2b). In contrast, no discernable peak and
a small number of antigen-specific CD8? T cells were
found in groups treated with LMD or that received no
treatment.
Both Tumor-Bearing and Non-Tumor-Bearing Mice
Treated with LMD-AH1 Have Higher Interferon-c
Expression in CD8? T Cells
We hypothesized that treatment with LMD-AH1, even
in a tumor-naive mouse, would activate CD8? T cells and
direct an antigen-specific adaptive immune response mea-
sured by ex vivo stimulation with the AH1 peptide. Tumor-
naive mice were injected with LMD or LMD-AH1 and
CD8? T-cell interferon-c production was measured by
intracellular staining. On day 6 (Fig. 2d), mice treated with
LMD-AH1 had more antigen-specific CD8? T-cell inter-
feron-c expression (P \ 0.001 LMD-AH1 vs. LMD, NT
and Naive). Similar results were observed when tumor-
challenged mice were treated with LMD-AH1 (Fig. 2d)
with peak interferon-c activity observed on day 9 after
tumor challenge (P \ 0.001 LMD-AH1 vs. LMD, NT and
Naive). These findings also correspond to the peak time of
antigen-specific CD8? T cells found on tetramer staining.
Mice treated with LMD alone had a later and smaller peak
on day 11, while NT mice lacked interferon-c production,
similar to non-tumor-bearing naive mice. Interestingly,
when interferon-c production from CD4? T cells was
examined, there were no differences between LMD-AH1
or LMD treated mice, and only slight increases when
compared to NT or naive mice (data not shown). When
interleukin-17 expression was examined on CD4? T cells,
no differences were observed between any groups (data not
shown).
Tumor-Specific CD8? T Cells Isolated from the Livers
and Spleens of Mice Treated with LMD-AH1 Have the
Highest Cytotoxic Killing Ability
To measure functional differences between lymphocytes
from mice treated with LMD-AH1, in vivo CTL assays
were performed on days 9 and 11 after hepatic tumor
challenge. In Fig. 3a, the mean percentage killing was
highest for LMD- AH1 on days 9 and 11 (5.05 and 6.05%)
(P \ 0.05 for LMD-AH1 vs. NT and Naive). In the spleen
(Fig. 3b), mean percentage killing was again highest for
the LMD-AH1 group on both days peaking on day 11 (1.96
and 5.59%) (P \ 0.05 for LMD-AH1 vs. LMD; LMD-AH1
vs. naive). Again, because targeted killing was observed for
LMD-AH1 treated mice, these results are consistent with
the presence of a robust, activated population of immune
cells.
Treatment with LMD-AH1 Leads to Long-Term
Antigen-Specific Memory and Immunity from Tumor
Rechallenge
After 12 weeks, mice that survived initial tumor chal-
lenge and treatment with LMD-AH1, LMD, or tumor-naive
mice underwent partial splenectomy. CD8? AH1 tetramer-
specific effector (CD62Llow CD95high) and central
(CD62Lhigh CD95high) memory T cells were identified
before and after flank challenge with CT26. At both time
points, higher percentages of both AH1-specific central and
effector memory T cells were found in mice previously
treated with LMD-AH1 (LMD-AH1 vs. naive P \ 0.05 on
day 11) (Fig. 4b,c). When mice were stratified by presence
or absence of tumor growth, by day 11, mice that rejected
tumor had higher numbers of AH1-specific effector
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memory CD8? T cells (P = 0.027) and trended toward a
greater number of AH1-specific central memory CD8? T
cells (Fig. 4b,c). Importantly, this effect was antigen-spe-
cific because when total central and effector memory
CD8? T-cell populations were examined there were no
differences between treatment groups and no correlation
between the absolute number of memory cells and whether
the tumor was rejected (Supplementary Fig. 3).
To further assess the generation of systemic memory
responses after initial rejection of hepatic metastases, ani-
mals treated with LMD-AH1 (n = 7) or LMD (n = 4) that
survived 125 days after hepatic tumor challenge were
given a rechallenge with 1 9 105 CT26 cells via tail vein
injection. Previously treated LMD-AH1 mice had 57%
survival versus 50% with LMD and 14% in the tumor-
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FIG. 2 Mice treated with LMD-AH1 have a high number and
sustained population of antigen-specific CD8? T cells with interferon-
c activity. a Percentage of AH1-specific CD8? T cells on day 9 in the
liver; n = 3 mice pooled per group. b Total number of AH1-specific
CD8? T cells on days 7, 9, and 11. c Diagram of Listeria injection
schedule of tumor-naive mice compared with CT26-challenged mice.
d Total number of CD8? T cells collected from the liver from tumor-
naive or CT26-challenged mice with intracellular staining for
interferon-c after AH1 peptide stimulation, n = 3 mice per group.
Two-way ANOVA Bonferroni posttest. *P \ 0.001 LMD-AH1 vs.
LMD and naive for day 6 for tumor-naive mice. Two-way ANOVA
Bonferroni posttest *P \ 0.001 LMD-AH1 versus LMD, NT and
naive for day 9 for CT26-challenged mice. P = NS unless otherwise
noted above
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LMD-AH1 that survived 110 days after initial hepatic
metastases challenge were rechallenged with 1 9 105
CT26 tumor cells subcutaneously on the flank (Fig. 5b) and
by day 27, 6 of 7 mice previously treated with LMD-AH1
rejected tumor versus 1 of 7 naive mice (P \ 0.001). When
mice given liver metastases that underwent late treatment
with LMD-AH1 with cyclophosphamide were rechal-
lenged, 67% survived (P \ 0.01) (Fig. 5c).
Treatment with L. monocytogenes Affects PD-1
and CTLA-4 Expression on CD8? T Cells in Mice
with Hepatic Metastases
PD-1 and CTLA-4 are coreceptors expressed on
exhausted CD8? T cells and have been found to be present
in large numbers in the tumor microenvironment and are
also found in chronically infected animals, rendering CD8?
T cells anergic. As LMD is known to cause inflammation
we wanted to characterize any change in the expression of
these receptors. CD8? T cells in the spleen showed little
difference in PD-1 expression between any group even
with increasing tumor burden (P = NS) (Fig. 6b). How-
ever, in the liver, NT mice showed an increase in both
the percentage and absolute number of CD8? T cell PD-1
expression over time, peaking at day 14, mirroring the
increase in tumor burden (Fig. 6a, b). In groups treated with
either LMD or LMD-AH1, little to no increase in PD-1
expression was observed (P \ 0.01 NT vs. LMD-AH1,
LMD, and naive in liver on day 14) (Fig. 6b).
CTLA-4 expression was measured on CD8? T cells, but
when compared to naive mice, all tumor-challenged groups
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FIG. 3 Mice treated with LMD-AH1 have the highest cytotoxic
activity in, in vivo cytotoxic T-cell assay. Mice (n = 5 per group per
day) were challenged with hepatic metastases and treated with LMD
or LMD-AH1 on day 3, 6, 9. On day 9 or 11 mice were injected with
CFSEhigh-labeled cells pulsed with AH1 peptide and CFSElow-labeled
cells pulsed with b-gal peptide. a Livers or b spleens were collected
and the ratio of CFSEhigh/CFSElow was used to determine percentage
killing by flow cytometry. Shown are individual data points with a
horizontal line representing the mean. Two-way ANOVA Bonferroni
posttest *P \ 0.05 for LMD-AH1 versus NT and naive in the liver
and **P \ 0.05 for LMD-AH1 versus LMD; LMD-AH1 versus naive
in the spleen. P = NS unless otherwise noted above
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reached a statistically significant increase in expression
(Fig. 6c). However, consistent with findings by Rowe et al.
in a primary attenuated L. monocytogenes infection study,
overall CTLA-4 expression on CD4? T cells was found to be
much higher than on CD8? T cells in the liver and spleen
(Fig. 6d).29 In the liver, all groups had higher expression of
CTLA-4 than naive mice, with LMD reaching statistically
significant expression on day 14 (P \ 0.05) (Fig. 6d). On
day 14, CTLA-4 expression in the spleens of mice treated
with LMD-AH1 had the highest expression among all groups
although overall the differences in the spleen were less
dramatic (P \ 0.05). As CTLA-4 expression was increased
in the liver tumor microenvironment, blockade of CTLA-4
would be a target to be used in combination with attenuated
L. monocytogenes.
DISCUSSION
Even with advances in liver directed therapies for the
treatment of hepatic colorectal metastases, hepatic tumor
burden is often rate limiting. We previously described
treatment with non-antigen-expressing LMD as an immu-
notherapeutic treatment for this disease, which could be
enhanced either by the depletion of regulatory T cells with
cyclophosphamide or in combination with a GM-CSF
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FIG. 4 Treatment with LMD-
AH1 promotes tumor antigen–
specific immunologic memory.
a Experimental design for parts
b–c. Values of the percentage of
b CD8? AH1-specific effector
memory (CD62Llow CD95high)
or c central memory (CD62 high
CD95high) T cells are shown by
treatment group or as a function
of tumor progression or
rejection, n = 7 LMD-AH1,
n = 5 LMD, n = 8 naive. Two-
way ANOVA with Bonferroni
posttest *P \ 0.05 for LMD-
AH1 versus naive on day 11 and
Mann-Whitney *P = 0.027 on
day 11 for percentage of tumor-
antigen-specific CD8? effector
memory T cells. Data for central
memory P = NS
Tumor-Associated Antigen Expressing L. monocytogenes S603
demonstrated that use of tumor antigen expressing LMD is
more effective in generating an initial effector response by
producing AH1 antigen-specific CD8? T cells in greater
numbers than a doubly attenuated strain alone. Further-
more, the activation, as measured by interferon-c, and the
killing ability of these CD8? T cells, as shown in the in
vivo CTL assay, in both the local tumor environment
within the liver and in the systemic circulation were both
augmented. In contrast to previous work, this antigen
expressing strain was able to enhance survival in both a
primary lung and flank tumor challenge study despite the
hepatotropic nature of L. monocytogenes. Additionally,
LMD-AH1 in combination with cyclophosphamide could
cure mice with far greater tumor burden (macroscopic
disease) whereas LMD with cyclophosphamide previously
cured just microscopic disease.14
Both the development of an initial response that eradi-
cates the primary tumor burden and the development of an
antigen-specific memory response are important for long-
term survival. Although, AH1-specific CD8? memory T
cells are initially generated by either form of the vaccine,
LMD or LMD-AH1. Figures 1–3 show the reliability and
overall generation of the initial tumor-specific CD8? T
cells was superior in LMD-AH1 treated mice. Mice treated
with LMD-AH1 were not only able to survive the original
hepatic tumor challenge, but were also able to reject tumor
when rechallenged in previously tumor-naive sites.
To specifically investigate the formation of these anti-
gen-specific memory T cells, we developed a novel
technique utilizing repeated surgical intervention. A por-
tion of the spleen was resected before and after tumor
rechallenge, giving us a large number of lymphocytes to
detect antigen-specific T cells, which was not technically
possible by using circulating blood or other sources. This
technique also allowed us to not only to quantify the
baseline antigen-specific total effector and central memory
populations but also to see whether a change in this
response occurred and if this was crucial for tumor
rejection. Our data indicate that the presence of higher
tumor-specific central and effector memory CD8?
T-cell populations was associated with tumor eradication
and that antigen-specific effector memory cells underwent
expansion.
The development of memory T cells and the magnitude
of cells needed for in vivo responses remain controversial.
However, these pathways involve both internal and exter-
nal stimuli within an inflammatory background with
signaling from CD4? T cells and cytokines released by
APCs.30–32 When L. monocytogenes was used in another
experimental model and compared with adenoviral vectors
for tumor antigen delivery, L. monocytogenes showed
enhanced memory responses.33 Although, this phenomenon
may be specific to certain tumor microenvironments, our
data supports the liver as a site where the generation of a
strong antigen-specific memory response may be depen-
dent on the generation of a Th1 background.33 We were
able to show that although our treatment causes inflam-
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FIG. 5 Treatment with LMD-AH1 protects against tumor rechal-
lenge. a On day 125, previously treated survivors of hepatic
metastases were rechallenged with CT26 pulmonary metastases and
survival was compared to tumor-naive mice, n = 7 LMD-AH1, naive
group, n = 4 LMD. Log-rank test *P = 0.044 for LMD-AH1 versus
naive. b On day 110, survivors of hepatic metastases previously
treated with LMD-AH1 were rechallenged with CT26 cells provided
through a subcutaneous flank injection, and tumor volume was
compared to tumor-naive mice, n = 7 for LMD-AH1 group and
n = 6 for NT group. Two-way ANOVA P = 0.034 with Bonferroni
posttest *P \ 0.05 on day 23 and **P \ 0.001 on day 27. c On day
140 after hepatic metastases challenge, survivors previously treated
with LMD-AH1 ? cyclophosphamide were rechallenged with CT26
pulmonary metastases, n = 6 LMD-AH1 ? Cy, n = 7 naive. Log-
rank *P \ 0.01. P = NS unless otherwise noted above
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FIG. 6 Listeria has
differential effects on
coreceptor expression in tumor-
bearing mice. a Listeria does
not cause an upregulation of
PD-1 expression on CD8? T
cells. Representative data shown
of CD8? T cells expressing PD-
1 on day 14 in the liver. b Total
CD8? T-cell PD-1 expression in
the liver and spleen. *P \ 0.01
NT versus LMD-AH1, LMD
and naive in liver on day 14.
c Total number of CD8? T cells
expressing the coreceptor
CTLA-4 *P \ 0.05 LMD
versus naive in liver and spleen.
d Total number CD4? T cells
expressing CTLA-4 *P \ 0.05
LMD versus LMD-AH1 and
NT; **P \ 0.05 naive versus
LMD-AH1, LMD, and NT in
liver and *P \ 0.05 LMD-AH1
versus LMD, NT, and naive in
spleen; n = 3 mice per group
per day. P = NS unless
otherwise noted
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has been implicated in tumor progression. Additionally, the
memory responses shown in our work are both durable and
specific because they persist without the need to boost or
reprime the immune system.
Interestingly, a decrease in the expression of
PD-1?CD8? T cells was observed in mice treated with
LMD-AH1. This decrease in PD-1 expression may be either
due to the decreased tumor burden causing less induction of
PD-1 on tumor infiltrating lymphocytes or possibly may be
the direct product of the attenuated L. monocytogenes itself
through cytokine signaling. L. monocytogenes may also
lead to changes in PD-1 expression through modulation of
PD-1’s receptors, B7-H1 and B7-DC, in the tumor micro-
environment. The combination of L. monocytogenes with
blockade of PD-1 or its receptors may be a viable treatment
approach.
Although, we saw less expression of PD-1, a treatment
associated decrease in another immune checkpoint recep-
tor, CTLA-4 was not found in our study. To the contrary,
we found an increase in CTLA-4 expression on both CD4?
and CD8? T-cell populations in all groups challenged with
tumor regardless of treatment amongst liver lymphocytes,
while little difference was found in the spleen. Given the
differences between CTLA-4 and PD-1 in their location
and temporal expression, these pathways may be differ-
entially affected by our treatment.34,35 The increased
CTLA-4 expression is important because just as the pres-
ence of tumor led to an increase in Foxp3?Tregs,
providing a target for combinatorial treatment with cyclo-
phosphamide, one could hypothesize that CTLA-4 would
be an additional candidate for blockade when using our
vaccine. This hypothesis is supported by previously pub-
lished findings.30,36 Rowe et al. showed that blockade of
CTLA-4 led to augmented antigen-specific CD4? and
CD8? T-cell responses directed toward an attenuated strain
of L. monocytogenes during primary infection.29 Pedicord
et al. reported that a single dose of anti-CTLA-4 antibody,
when administered with Listeria monocytogenes, enhanced
bacterial clearance upon rechallenge as a result of an
increase in the production of effector memory T cells.37
Conceivably, the blockade of CTLA-4 could increase
antigen-specific responses to tumor-associated antigens
delivered by L. monocytogenes allowing for stronger initial
antitumor responses or for smaller doses of antigen
expressing L. monocytogenes to be administered, thus
increasing the safety profile with the use of this bacterium.
The initial enhanced response combined with increased
effector memory T cells, could not only lead to improved
initial tumor eradication but also to the prevention of
recurrent disease.
Although, the identification of cancer associated anti-
gens for targeted therapies has progressed, any successful
treatment will need to overcome the barriers presented by
MHC I downregulation, and coreceptor signaling between
tumor cells, T cells and APCs leading to continued immune
evasion. In our study, the efficacy shown using this
genetically attenuated strain of AH1 expressing L. mono-
cytogenes suggests that it can be engineered to synthesize a
sufficient amount of tumor-associated antigen through a
strong promoter. Additionally, other groups have shown
that L. monocytogenes can be engineered to express poly-
valent tumor-specific antigens.19,36 Despite this, advances
in genetic engineering of L. monocytogenes are needed to
determine the relative importance of virulence factors to
enable toll-like receptor signaling while maintaining the
ability to reliably deliver antigen.
In summary, we have shown that tumor-associated
antigen expressing genetically attenuated Listeria mono-
cytogenes used in a murine model of colorectal cancer
metastasis is effective to initially treat and subsequently
prevent tumor recurrence. This efficacy was demonstrated
by inducing three major immune mechanisms: innate,
adaptive, and tumor-specific immune memory. The success
in this preclinical model continues to show promise in the
development of L. monocytogenes-based treatment plat-
forms into effective vaccines in human clinical trials and in
finding novel combinatorial regimens to further enhance its
observed efficacy.
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